SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-070263
Filing Date
2024-08-16
Accepted
2024-08-16 16:25:22
Documents
14
Period of Report
2024-08-16
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0211617-8k425_arcabio.htm   iXBRL 8-K 51402
2 PRESS RELEASE, ISSUED ON AUGUST 16, 2024 ea021161701ex99-1_arcabio.htm EX-99.1 22113
  Complete submission text file 0001213900-24-070263.txt   260731

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE abio-20240816.xsd EX-101.SCH 3012
4 XBRL LABEL FILE abio-20240816_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE abio-20240816_pre.xml EX-101.PRE 22357
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0211617-8k425_arcabio_htm.xml XML 3652
Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 241217016
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)